(3R,4R,5R,6R)-氮杂环庚烷-3,4,5,6-四醇盐酸盐 | 178964-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: (3R,4R,5R,6R)-氮杂环庚烷-3,4,5,6-四醇盐酸盐
• 英文名称: (3R,4R,5R,6R)-tetrahydroxyazepane (1,6-dideoxy-1,6-imino-D-mannitol)
• 英文别名: (3R,4R,5R,6R)-3,4,5,6-Tetrahydroxyazepane hydrochloride；(3R,4R,5R,6R)-tetrahydroxyazepane hydrochloride；1,6-dideoxy-1,6-imino-D-mannitol hydrochloride；(3R,4R,5R,6R)-3,4,5,6-Tetrahydroxyazepane hcl；(3R,4R,5R,6R)-azepane-3,4,5,6-tetrol;hydrochloride
• CAS: 178964-40-4
• 化学式: C₆H₁₃NO₄*ClH
• 分子量: 199.634
• InChiKey: UJBGXSDFDJMWFZ-MVNLRXSJSA-N

物化性质

• 沸点：
  328.6±42.0 °C(Predicted)
• 密度：
  1.508±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.99
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  97.5
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  D-甘露糖-1,4-内酯 在 palladium on activated charcoal 叠氮化锂 、 硼烷四氢呋喃络合物 、 四溴化碳 、 氢气 、 对甲苯磺酸 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 80.0h， 生成 (3R,4R,5R,6R)-氮杂环庚烷-3,4,5,6-四醇盐酸盐
  参考文献：
  名称：

  Syntheses of (3R,4R,5R,6R)-tetrahydroxyazepane (1,6-dideoxy-1,6-imino-d-mannitol) and (3S,4R,5R,6R)-tetrahydroxyazepane (1,6-dideoxy-1,6-imino-d-glucitol)

  摘要：

  Syntheses of 1,6-dideoxy-1,6-imino-D-mannitol (D-mannoazepane) (1) and 1,6-dideoxy-1,6-imino-D-glucitol (D-glucoazepane) (3) from D-isoascorbic acid and D-glucono-1,5-lactone, respectively, are described. The key step in both routes involved reductive aminative 1,6-cyclization with retention of configurations to give the corresponding lactams, which were subsequently reduced to afford compounds 1 and 3 in 24 and 28.5%, overall yield, respectively. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00757-3

文献信息

• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS DE LIAISON À UNE OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013058809A1

  公开（公告）日：2013-04-25

  Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  披露了一些化合物，可用于治疗由于或与在眼睛中积累的有毒视觉循环产物有关的眼科疾病，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂联合使用的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013081642A1

  公开（公告）日：2013-06-06

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  揭示了用于治疗由于或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的化合物和组合物，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。
• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS DE LIAISON AUX OPSINES, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013082000A1

  公开（公告）日：2013-06-06

  Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  披露了一些化合物，这些化合物对治疗由于或与在眼睛中积累的有毒视觉循环产物有关的眼科疾病非常有用，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂联合使用的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS DE LIAISON À L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2010147653A1

  公开（公告）日：2010-12-23

  Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described.

  本文披露了用于治疗与视蛋白蛋白质错位、突变视蛋白蛋白质的错误折叠以及在眼睛中积累的有毒视觉循环产物有关的眼科疾病的化合物及该化合物的组合物，以及使用该化合物的方法。还描述了在这些方法中有用的化合物和组合物，无论是单独使用还是与其他治疗剂联合使用。
• Regioselective azidotrimethylsilylation of carbohydrates and applications thereof
  作者：Mallikharjuna Rao L、Syed Khalid Yousuf、Debaraj Mukherjee、Subhash Chandra Taneja

  DOI：10.1039/c2ob26324f

  日期：——

  Azidotrimethylsilylation of carbohydrates (monosaccharides and disaccharides) has been achieved in high yields under Mitsunobu conditions. The azidation of carbohydrates is effected at 0 °C essentially only at the primary alcoholic position in mono, di- and triols in protected/unprotected glycosides, whereas the remaining secondary hydroxyl groups got silylated. Surprisingly, no azidation of the secondary hydroxyls was observed in all the carbohydrate substrates. Applications of the methodology for the synthesis of amino sugars, triazoles and azasugars are reported.

  在Mitsunobu条件下，实现了碳水化合物（单糖和双糖）高产率的叠加三甲基硅烷化。碳水化合物的叠加在0 °C下仅在单醇、二醇和三醇的初级醇位点进行，保护/未保护的糖苷中，剩余的二级羟基则被硅烷化。令人惊讶的是，在所有碳水化合物底物中没有观测到二级羟基的叠加反应。该方法的应用已用于氨基糖、三唑和氮糖的合成。